THE FOLLOW UP
STATEMENT

Nine MFN pricing agreements announced with major pharmaceutical companies to lower prescription drug prices.

True

Evidence from credible sources supports the statement as accurate. Learn more in Methodology.

Interesting: 0/0 • Support: 0/0Log in to vote
direct_action

Nine MFN pricing agreements executed as described in the release.

Source summary
President Donald J. Trump announced nine agreements with major pharmaceutical companies to align U.S. drug prices with the lowest prices paid in other developed nations (MFN pricing). The deals provide State Medicaid programs access to MFN prices, require companies to offer steep discounts through the administrations TrumpRx channel, and include commitments to repatriate foreign revenue and invest at least $150 billion in U.S. manufacturing. Companies will also donate active pharmaceutical ingredients to a Strategic Active Pharmaceutical Ingredients Reserve (SAPIR). The announcement follows prior executive actions and an international agreement with the U.K. to raise net prices there.
View original article →
Latest fact check

On December 19, 2025, President Donald J. Trump announced nine new agreements with major pharmaceutical companies—Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, and Sanofi—to lower prescription drug prices for Americans in line with the most-favored-nation (MFN) pricing model. These agreements aim to reduce prices on medications for conditions such as type two diabetes, rheumatoid arthritis, multiple sclerosis, asthma, chronic obstructive pulmonary disease (COPD), hepatitis B and C, HIV, and certain cancers. Additionally, the agreements ensure that every State Medicaid program will have access to MFN drug prices on products from these companies, resulting in significant savings. The companies are also required to repatriate increased foreign revenue on existing products and offer medicines at deep discounts when selling directly to American patients through TrumpRx. (whitehouse.gov)

Sources

Timeline

  1. Update · Dec 21, 2025, 08:59 AMTrue
    On December 19, 2025, President Donald J. Trump announced nine new agreements with major pharmaceutical companies—Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, and Sanofi—to lower prescription drug prices for Americans in line with the most-favored-nation (MFN) pricing model. These agreements aim to reduce prices on medications for conditions such as type two diabetes, rheumatoid arthritis, multiple sclerosis, asthma, chronic obstructive pulmonary disease (COPD), hepatitis B and C, HIV, and certain cancers. Additionally, the agreements ensure that every State Medicaid program will have access to MFN drug prices on products from these companies, resulting in significant savings. The companies are also required to repatriate increased foreign revenue on existing products and offer medicines at deep discounts when selling directly to American patients through TrumpRx. (whitehouse.gov)
  2. Update · Dec 21, 2025, 07:49 AMTrue
    On December 19, 2025, President Donald J. Trump announced nine new agreements with major pharmaceutical companies—Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, and Sanofi—to lower prescription drug prices for Americans, aligning them with the lowest prices paid by other developed nations, known as most-favored-nation (MFN) pricing. (whitehouse.gov) These agreements aim to reduce costs for drugs treating various conditions, including type two diabetes, rheumatoid arthritis, multiple sclerosis, asthma, chronic obstructive pulmonary disease (COPD), hepatitis B and C, HIV, and certain cancers. Additionally, the companies are required to offer medicines at deep discounts when sold directly to American patients through the TrumpRx platform. (whitehouse.gov) Therefore, the statement that nine MFN pricing agreements were announced with major pharmaceutical companies to lower prescription drug prices is accurate.
  3. Update · Dec 21, 2025, 07:03 AMTrue
    On December 19, 2025, President Donald J. Trump announced nine new agreements with major pharmaceutical companies—Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, and Sanofi—to lower prescription drug prices for Americans, aligning them with the most-favored-nation (MFN) pricing model. These agreements aim to reduce prices on medications for conditions such as type two diabetes, rheumatoid arthritis, multiple sclerosis, asthma, chronic obstructive pulmonary disease (COPD), hepatitis B and C, HIV, and certain cancers. Additionally, the deals ensure that all new innovative medicines from these companies will be priced according to the MFN model, and they require the companies to repatriate increased foreign revenue on existing products for the benefit of American patients. Patients purchasing directly through TrumpRx will also see significant price reductions on various medications. (whitehouse.gov)
  4. Update · Dec 21, 2025, 05:55 AMTrue
    On December 19, 2025, President Donald J. Trump announced agreements with nine major pharmaceutical companies—Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, and Sanofi—to lower prescription drug prices in the U.S. to align with the lowest prices paid by other developed nations, known as most-favored-nation (MFN) pricing. These agreements aim to reduce costs for drugs treating conditions such as type two diabetes, rheumatoid arthritis, multiple sclerosis, asthma, chronic obstructive pulmonary disease (COPD), hepatitis B and C, HIV, and certain cancers. Additionally, the companies are required to offer medicines at deep discounts when sold directly to American patients through the TrumpRx platform. (whitehouse.gov)
  5. Update · Dec 21, 2025, 05:07 AMTrue
    The White House announced on December 19, 2025, that nine major pharmaceutical companies—Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, and Sanofi—have agreed to lower prescription drug prices for Americans to align with the lowest prices paid by other developed nations, known as most-favored-nation (MFN) pricing. These agreements aim to reduce costs for treatments of various conditions, including type two diabetes, rheumatoid arthritis, multiple sclerosis, asthma, COPD, hepatitis B and C, HIV, and certain cancers. Additionally, the agreements ensure that all new innovative medicines from these companies will be priced according to MFN standards, and they require the companies to repatriate increased foreign revenue on existing products for the benefit of American patients. Patients purchasing directly through TrumpRx will see significant price reductions on numerous products. (whitehouse.gov)
  6. Update · Dec 21, 2025, 04:25 AMTrue
    On December 19, 2025, President Donald J. Trump announced agreements with nine major pharmaceutical companies—Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, and Sanofi—to lower prescription drug prices in the U.S. to align with the lowest prices paid by other developed nations, known as most-favored-nation (MFN) pricing. These agreements aim to reduce costs for drugs treating conditions such as type two diabetes, rheumatoid arthritis, multiple sclerosis, asthma, chronic obstructive pulmonary disease (COPD), hepatitis B and C, HIV, and certain cancers. Additionally, the companies committed to offering deep discounts on their medications through the direct-to-consumer TrumpRx platform. (whitehouse.gov)
  7. Update · Dec 21, 2025, 02:56 AMTrue
    On December 19, 2025, President Donald J. Trump announced agreements with nine major pharmaceutical companies—Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, and Sanofi—to lower prescription drug prices in the U.S. to align with the lowest prices paid by other developed nations, known as most-favored-nation (MFN) pricing. These agreements aim to reduce costs for drugs treating conditions such as type two diabetes, rheumatoid arthritis, multiple sclerosis, asthma, chronic obstructive pulmonary disease (COPD), hepatitis B and C, HIV, and certain cancers. The companies have committed to providing MFN drug prices to every state Medicaid program, ensuring that foreign nations can no longer use price controls to free ride on American innovation by guaranteeing MFN prices on all new innovative medicines they bring to market. Additionally, the agreements require the companies to repatriate increased foreign revenue on existing products resulting from U.S. trade policies for the benefit of American patients and to offer medicines at deep discounts off the list price when selling directly to American patients through the TrumpRx platform. (whitehouse.gov)
  8. Update · Dec 20, 2025, 11:49 PMTrue
    The White House announced on December 19, 2025, that President Donald J. Trump secured nine new agreements with major pharmaceutical companies—Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, and Sanofi—to align U.S. prescription drug prices with the lowest prices paid by other developed nations, known as most-favored-nation (MFN) pricing. These agreements aim to reduce costs for treatments of conditions such as type two diabetes, rheumatoid arthritis, multiple sclerosis, asthma, chronic obstructive pulmonary disease (COPD), hepatitis B and C, HIV, and certain cancers. Additionally, the agreements ensure that all new innovative medicines from these companies will be priced according to MFN standards, and that increased foreign revenue from existing products will be repatriated to benefit American patients. Patients purchasing directly through TrumpRx will also see significant price reductions on various medications. (whitehouse.gov)
  9. Update · Dec 20, 2025, 08:46 AMcomplete
    On December 19, 2025, President Donald J. Trump announced nine new agreements with major pharmaceutical companies—Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, and Sanofi—to lower prescription drug prices for Americans in line with the lowest prices paid by other developed nations, known as most-favored-nation (MFN) pricing. These agreements aim to reduce prices on drugs treating various conditions, including type two diabetes, rheumatoid arthritis, multiple sclerosis, asthma, chronic obstructive pulmonary disease (COPD), hepatitis B and C, HIV, and certain cancers. The initiatives are expected to provide every State Medicaid program access to MFN drug prices, resulting in significant savings and strengthening the program for vulnerable populations. Additionally, the agreements require the companies to repatriate increased foreign revenue on existing products and offer medicines at deep discounts when selling directly to American patients through the upcoming TrumpRx platform. (whitehouse.gov)
  10. Original article · Dec 19, 2025
    View article
Back to Countdowns

Comments

Only logged-in users can comment.
Loading…